JP2012519712A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012519712A5 JP2012519712A5 JP2011553163A JP2011553163A JP2012519712A5 JP 2012519712 A5 JP2012519712 A5 JP 2012519712A5 JP 2011553163 A JP2011553163 A JP 2011553163A JP 2011553163 A JP2011553163 A JP 2011553163A JP 2012519712 A5 JP2012519712 A5 JP 2012519712A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- seq
- antibody
- sugar chain
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15815309P | 2009-03-06 | 2009-03-06 | |
| US61/158,153 | 2009-03-06 | ||
| PCT/US2010/026492 WO2010102276A2 (en) | 2009-03-06 | 2010-03-08 | Humanized anti-cd19 antibody formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012519712A JP2012519712A (ja) | 2012-08-30 |
| JP2012519712A5 true JP2012519712A5 (enExample) | 2013-05-02 |
Family
ID=42710248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011553163A Withdrawn JP2012519712A (ja) | 2009-03-06 | 2010-03-08 | ヒト化抗ｃｄ１９抗体製剤 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20120148576A1 (enExample) |
| EP (1) | EP2403532A4 (enExample) |
| JP (1) | JP2012519712A (enExample) |
| KR (1) | KR20110125664A (enExample) |
| CN (1) | CN102413839A (enExample) |
| AU (1) | AU2010221099A1 (enExample) |
| BR (1) | BRPI1013237A2 (enExample) |
| CA (1) | CA2754266A1 (enExample) |
| MX (1) | MX2011009312A (enExample) |
| RU (1) | RU2011140486A (enExample) |
| WO (1) | WO2010102276A2 (enExample) |
| ZA (1) | ZA201106480B (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100038816A1 (en) * | 2006-08-16 | 2010-02-18 | Novartis Ag | Method of making solid dispersions of highly crystalline therapeutic compounds |
| UY32560A (es) | 2009-04-29 | 2010-11-30 | Bayer Schering Pharma Ag | Inmunoconjugados de antimesotelina y usos de los mismos |
| SG10201710439UA (en) * | 2010-05-25 | 2018-01-30 | Genentech Inc | Methods of purifying polypeptides |
| MY194408A (en) | 2011-10-14 | 2022-11-30 | Genentech Inc | Uses for and Article of Manufacture Including Her2 Dimerization Inhibitor Pertuzumab |
| US20130195851A1 (en) * | 2011-12-23 | 2013-08-01 | Genentech, Inc. | Articles of manufacture and methods for co-administration of antibodies |
| WO2013138244A2 (en) * | 2012-03-12 | 2013-09-19 | Medimmune, Llc | Treatment of multiple sclerosis with anti-cd19 antibody |
| WO2013163088A1 (en) * | 2012-04-23 | 2013-10-31 | Zogenix, Inc. | Piston closures for drug delivery capsules |
| AU2013289984B2 (en) * | 2012-07-13 | 2018-03-08 | The Trustees Of The University Of Pennsylvania | Use of CART19 to deplete normal B cells to induce tolerance |
| AU2013201465B2 (en) * | 2012-10-24 | 2016-03-03 | Rayner Intraocular Lenses Limited | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| CN105209069B (zh) | 2013-03-13 | 2019-08-23 | 豪夫迈·罗氏有限公司 | 抗体配制剂 |
| CA2942150A1 (en) * | 2014-04-07 | 2015-10-15 | Seattle Genetics, Inc. | Stable formulations for anti-cd19 antibodies and antibody-drug conjugates |
| WO2015181757A1 (en) * | 2014-05-28 | 2015-12-03 | Nono Inc. | Lyophilized formulation of tat-nr2b9c with acetylation scavenger |
| JP7072384B2 (ja) | 2014-09-15 | 2022-05-20 | ジェネンテック， インコーポレイテッド | 抗体製剤 |
| TWI809304B (zh) | 2014-12-01 | 2023-07-21 | 奥默羅斯公司 | 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液 |
| US11091543B2 (en) | 2015-05-07 | 2021-08-17 | Swedish Orphan Biovitrum Ag | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
| BR112017023867A2 (pt) | 2015-05-07 | 2018-07-24 | Novimmune Sa | métodos e composições para diagnóstico e tratamento de distúrbios em pacientes com níveis elevados de cxcl9 e outros biomarcadores |
| AR104847A1 (es) * | 2015-06-17 | 2017-08-16 | Lilly Co Eli | Formulación de anticuerpo anti-cgrp |
| EP3149046B1 (en) * | 2015-07-24 | 2020-02-26 | Innovative Cellular Therapeutics Co., Ltd. | Humanized anti-cd19 antibody and use thereof |
| US10493139B2 (en) | 2015-07-24 | 2019-12-03 | Innovative Cellular Therapeutics CO., LTD. | Humanized anti-CD19 antibody and use thereof with chimeric antigen receptor |
| CN109415440B (zh) * | 2016-06-27 | 2022-12-06 | 莫佛塞斯公司 | 抗-cd19抗体制剂 |
| EP3330289A1 (en) * | 2016-12-02 | 2018-06-06 | Friedrich-Alexander-Universität Erlangen-Nürnberg | A cd33-, cd16- and cd123-specific single chain triplebody |
| CN116531511A (zh) | 2017-03-02 | 2023-08-04 | 豪夫迈·罗氏有限公司 | Her2阳性乳腺癌的辅助治疗 |
| JOP20190260A1 (ar) * | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
| AU2018263868A1 (en) | 2017-05-02 | 2019-12-12 | Merck Sharp & Dohme Llc | Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies |
| JP7279011B2 (ja) | 2017-07-10 | 2023-05-22 | インターナショナル－ドラッグ－ディベロップメント－バイオテック | 抗ｃｄ２０抗体または化学療法薬と併用して非フコシル化アポトーシス促進性抗ｃｄ１９抗体を用いるｂ細胞悪性の治療 |
| CN111465616B (zh) * | 2017-12-06 | 2023-08-01 | 艾克隆株式会社 | 特异性识别恶性b细胞的抗体或其抗原结合片段、包含其的嵌合抗原受体及其用途 |
| CN113015748B (zh) | 2018-10-31 | 2025-12-12 | 默沙东有限责任公司 | 抗人pd-1抗体晶体及其使用方法 |
| CN113316458B (zh) | 2018-11-07 | 2024-08-02 | 默沙东有限责任公司 | 抗lag3抗体和抗pd-1抗体的共制剂 |
| SG11202108627SA (en) | 2019-02-18 | 2021-09-29 | Lilly Co Eli | Therapeutic antibody formulation |
| KR20220004113A (ko) * | 2019-04-24 | 2022-01-11 | 비엘라 바이오, 인크. | 자가면역 질환을 치료하기 위한 항-cd19 항체의 용도 |
| WO2021067598A1 (en) | 2019-10-04 | 2021-04-08 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant aav |
| JP2022553821A (ja) * | 2019-11-05 | 2022-12-26 | ブリストル－マイヤーズ スクイブ カンパニー | Ｍ－タンパク質アッセイおよびその使用 |
| IL300245A (en) * | 2020-07-31 | 2023-03-01 | Alamab Therapeutics Inc | Anti-connexin antibody formulations |
| JP2024505128A (ja) * | 2020-12-30 | 2024-02-05 | アイ－エムエービー バイオファーマ カンパニー リミテッド | 抗ｃｄ７３抗体の製剤 |
| WO2022223028A1 (zh) * | 2021-04-23 | 2022-10-27 | 上海君实生物医药科技股份有限公司 | 抗BLyS抗体、其药物组合物及其用途 |
| CN113208810B (zh) * | 2021-05-18 | 2022-04-12 | 南方医科大学深圳医院 | 一种用于smile术透镜染色低温分离液的超声波给药装置 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6171586B1 (en) * | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| EP2216342B1 (en) * | 2003-07-31 | 2015-04-22 | Immunomedics, Inc. | Anti-CD19 antibodies |
| AU2007294575B2 (en) * | 2006-09-08 | 2013-06-27 | Viela Bio, Inc. | Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
-
2010
- 2010-03-08 CN CN2010800197310A patent/CN102413839A/zh active Pending
- 2010-03-08 AU AU2010221099A patent/AU2010221099A1/en not_active Abandoned
- 2010-03-08 RU RU2011140486/15A patent/RU2011140486A/ru unknown
- 2010-03-08 EP EP10749432A patent/EP2403532A4/en not_active Withdrawn
- 2010-03-08 WO PCT/US2010/026492 patent/WO2010102276A2/en not_active Ceased
- 2010-03-08 US US13/254,656 patent/US20120148576A1/en not_active Abandoned
- 2010-03-08 MX MX2011009312A patent/MX2011009312A/es not_active Application Discontinuation
- 2010-03-08 CA CA2754266A patent/CA2754266A1/en not_active Abandoned
- 2010-03-08 BR BRPI1013237A patent/BRPI1013237A2/pt not_active IP Right Cessation
- 2010-03-08 JP JP2011553163A patent/JP2012519712A/ja not_active Withdrawn
- 2010-03-08 KR KR1020117023323A patent/KR20110125664A/ko not_active Withdrawn
-
2011
- 2011-09-05 ZA ZA2011/06480A patent/ZA201106480B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012519712A5 (enExample) | ||
| CN110418803B (zh) | 抗rsv单克隆抗体配制品 | |
| RU2011140486A (ru) | Композиции, содержащие гуманизированные антитела к cd19 | |
| TWI633891B (zh) | 藉由投與ｉｌ－４ｒ抑制劑以治療過敏及增強過敏原－特異之免疫療法的方法 | |
| RU2012131099A (ru) | Препарат антитела | |
| JP2019527678A5 (enExample) | ||
| KR20200123170A (ko) | B7-h4 항체 제형 | |
| US20250136706A1 (en) | Methods For Prevention Of Graft Rejection In Xenotransplantation | |
| AU2018244276A1 (en) | Methods and compositions for reduction of immunogenicity | |
| TW201406398A (zh) | 醫藥調配物 | |
| JP2006528627A5 (enExample) | ||
| JP2023516195A (ja) | Ｃ１９ ｃ３８二特異性抗体 | |
| TWI726426B (zh) | 包含抗ｏｘ４０抗體的製劑、其製備方法及其用途 | |
| TW202508630A (zh) | 治療表現ｃｄ２０之ｂ細胞癌症之方法 | |
| TW202021620A (zh) | 一種cd40抗體藥物組合物及其用途 | |
| TW202034925A (zh) | Ｃｄｋ４／６抑制劑聯合免疫治療在製備治療淋巴瘤的藥物中的用途 | |
| TWI895541B (zh) | 包含抗原和其醣工程化抗體之免疫組合物 | |
| TW202114734A (zh) | Il-17拮抗劑治療自身免疫疾病的方法 | |
| TWI911431B (zh) | 抗rsv單株抗體配製物 | |
| HK40110786A (zh) | 抗rsv单克隆抗体配制品 | |
| HK40093820A (zh) | 抗rsv单克隆抗体配制品 | |
| HK40011725B (zh) | 抗rsv单克隆抗体配制品 | |
| HK40011725A (en) | Anti-rsv monoclonal antibody formulation | |
| EA043164B1 (ru) | Способы и композиции для снижения иммуногенности | |
| HK40002161A (en) | Anti-rsv monoclonal antibody formulation |